<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2413-4341</journal-id>
<journal-title><![CDATA[Revista Paraguaya de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. parag. reumatol.]]></abbrev-journal-title>
<issn>2413-4341</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Paraguaya de Reumatología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2413-43412022000200072</article-id>
<article-id pub-id-type="doi">10.18004/rpr/2022.08.02.72</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efectos adversos al metotrexate en una consulta externa de Reumatología]]></article-title>
<article-title xml:lang="en"><![CDATA[Adverse effects of methotrexate in a rheumatology outpatient clinic ABSTRACT]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez-Femayor]]></surname>
<given-names><![CDATA[Kleyramal D. J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aray-Álvarez]]></surname>
<given-names><![CDATA[Joselen A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fuentes-Silva]]></surname>
<given-names><![CDATA[Yurilís J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Oriente Departamento de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad Bolívar ]]></addr-line>
<country>Venezuela</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>8</volume>
<numero>2</numero>
<fpage>72</fpage>
<lpage>76</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S2413-43412022000200072&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S2413-43412022000200072&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S2413-43412022000200072&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Introducción: El metotrexate (MTX) es un fármaco ampliamente utilizado en el tratamiento de diversas enfermedades reumáticas como artritis reumatoide y artritis psoriásica, siendo un medicamento bien tolerado, económico y con eficacia comprobada en el control de los síntomas articulares y extraarticulares. Metodología: Se realizó un estudio descriptivo, retrospectivo, transversal; se revisaron 1.441 historias médicas de una Consulta Externa Privada de Reumatología en el Centro Clínico Universitario de Oriente en Ciudad Bolívar, Venezuela en el periodo diciembre 2011 a diciembre 2019; de esas historias se seleccionaron 202 historias de pacientes que recibieron MTX, excluyéndose 52 historias porque no cumplieron consultas sucesivas, quedando para el análisis 150 historias. Resultados: la muestra estuvo representada por 150 pacientes, cuya edad promedio fue de 50,2±14,3 años, el sexo predominante fue el femenino con 83,3% (n=125). La principal indicación del metotrexate fue para el tratamiento de artritis reumatoide con 56,0% (n=84). Se presentaron efectos adversos en 16,7% de los casos, siendo la intolerancia gástrica el más frecuente con 36,0% (9 pacientes). No se encontró relación con la dosis del metotrexate y la presentación de efectos adversos. Conclusión: Se evidenció una baja tasa de efectos adversos al MTX en pacientes con enfermedades reumáticas, no relacionado a la dosis y en menos del 10% de los casos fue necesario realizar cambio de tratamiento.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Introduction: Methotrexate (MTX) is a drug widely used in the treatment of various rheumatic diseases such as rheumatoid arthritis and psoriatic arthritis, being a well-tolerated, inexpensive drug with proven efficacy in the control of joint and extra-articular symptoms. Methodology: A descriptive, retrospective, cross-sectional study was conducted, 1,441 medical records were reviewed from a Rheumatology Private Outpatient Clinic at the Centro Clínico Universitario de Oriente in Ciudad Bolivar, Venezuela in the period December 2011 to December 2019; from these records, 202 records of patients who received MTX were selected, excluding 52 records because they did not complete successive consultations, leaving 150 records for the analysis. Results: the sample was represented by 150 patients, whose average age was 50.2±14.3 years, the predominant sex was female with 83.3% (n=125). The main indication for me- thotrexate was for the treatment of rheumatoid arthritis with 56.0% (n=84). Adverse effects occurred in 16.7% of cases, with gastric intolerance being the most frequent with 36.0% (9 patients). No relationship was found with the dose of methotrexate and the presentation of adverse effects. Conclusion: A low rate of adverse effects to MTX was evidenced in patients with rheumatic diseases, not related to the dose, and in less than 10% of the cases it was necessary to change treatment.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[metotrexate]]></kwd>
<kwd lng="es"><![CDATA[efectos adversos]]></kwd>
<kwd lng="es"><![CDATA[artritis]]></kwd>
<kwd lng="es"><![CDATA[artritis reumatoide]]></kwd>
<kwd lng="en"><![CDATA[methotrexate]]></kwd>
<kwd lng="en"><![CDATA[side effects]]></kwd>
<kwd lng="en"><![CDATA[arthritis]]></kwd>
<kwd lng="en"><![CDATA[rheumatoid arthritis.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weinblatt]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methotrexate in rheumatoid arthritis: A quarter century of development]]></article-title>
<source><![CDATA[Trans AmClin Climatol Assoc]]></source>
<year>2013</year>
<volume>124</volume>
<page-range>16-25</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandoval]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metotrexato y su uso en el tratamiento de enfermedades reumáticas]]></article-title>
<source><![CDATA[Ann Fac Med]]></source>
<year>1996</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>116-23</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saldaña]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Arellano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de metotrexato, azatioprina y micofenolato de mofetilo en dermatología]]></article-title>
<source><![CDATA[Dermatol CMQ]]></source>
<year>2017</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-54</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Restrepo]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacogenética del metotrexato en artritis reumatoide (Revisión sistemática)]]></article-title>
<source><![CDATA[Rev Col Reumatol]]></source>
<year>2016</year>
<volume>23</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>102-14</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[¿Cómo hacer buen uso del metotrexato en artritis Reumatoide?]]></article-title>
<source><![CDATA[Reumatol Clín]]></source>
<year>2012</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>42-5</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tornero]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recomendaciones para el uso del metotrexato en artritis reumatoide: incremento y reducción de dosis y vías de administración]]></article-title>
<source><![CDATA[Reumatol Clín]]></source>
<year>2016</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento de la artritis reumatoide del anciano]]></article-title>
<source><![CDATA[Sem Fund Esp Reumatol]]></source>
<year>2011</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>103-7</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rangel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Factores asociados a tolerancia gastrointestinal con dosis cotidiana de metotrexato en pacientes con artritis reumatoide]]></source>
<year>2016</year>
<page-range>pp 45</page-range><publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Fac. Med. San Luis Potosi]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tornero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Andreu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Corominas]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Román]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metotrexato en pacientes con artritis reumatoide en España: subanálisis del proyecto AR Excellence]]></article-title>
<source><![CDATA[Reumatol clin]]></source>
<year>2019</year>
<volume>15</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>338-42</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[England]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Tiong]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Curtis]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Kazi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mikuls]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures]]></article-title>
<source><![CDATA[Arthritis Care Res (Hoboken)]]></source>
<year>2019</year>
<volume>71</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1540-55</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Landewé]]></surname>
<given-names><![CDATA[RBM]]></given-names>
</name>
<name>
<surname><![CDATA[Bijlsma]]></surname>
<given-names><![CDATA[JWJ]]></given-names>
</name>
<name>
<surname><![CDATA[Burmester]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Dougados]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kerschbaumer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2020</year>
<volume>79</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>685-99</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nagy]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Roodenrijs]]></surname>
<given-names><![CDATA[NMT]]></given-names>
</name>
<name>
<surname><![CDATA[Welsing]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Kedves]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hamar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[van der Goes]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR definition of difficult-to-treat rheumatoid arthritis]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2021</year>
<volume>80</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Guyatt]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ogdie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gladman]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
<name>
<surname><![CDATA[Deal]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Deodhar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Special Article: 2018 American College of Rheumatology/ National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis]]></article-title>
<source><![CDATA[Arthritis Care Res (Hoboken)]]></source>
<year>2019</year>
<volume>71</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>2-29</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogdie]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Coates]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Gladman]]></surname>
<given-names><![CDATA[DD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment guidelines in psoriatic arthritis]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2020</year>
<volume>1</volume>
<numero>59(Suppl 1)</numero>
<issue>59(Suppl 1)</issue>
<page-range>i37-46</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrero]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wittoek]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Allado]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cruzel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Breuil]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Euller Ziegler]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial]]></article-title>
<source><![CDATA[Arthritis Rheumatol]]></source>
<year>2019</year>
<volume>71</volume>
<numero>suppl 10</numero>
<issue>suppl 10</issue>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferrero]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wittoek]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Allado]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cruzel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fontas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Breuil]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ziegler]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kremer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Loeuille]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Roux]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>2021</year>
<volume>51</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>831-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barral]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Canet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Enriquez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Inocencio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metotrexato en artritis idiopática juvenil: efectos adversos y factores asociados]]></article-title>
<source><![CDATA[An Ped]]></source>
<year>2020</year>
<volume>92</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>124-31</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wadsack]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Loffler]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe MTX Toxicity in Rheumatic Diseases - Analysis of 22 Cases]]></article-title>
<source><![CDATA[Reum Dis Treat]]></source>
<year>2019</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solomon]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Glynn]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Karlson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Corrigan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Colls]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse Effects of Low-Dose Methotrexate: A Randomized Trial]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2020</year>
<volume>172</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>369-80</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
